cidofovir (vistide) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cidofovir is an antiviral nucleotide analogue with significant activity against cytomegalovirus (CMV) and other herpesviruses. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. Cidofovir is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.   NCATS

Chemistry

  • SMILES: NC1=NC(=O)N(C[C@@H](CO)OCP(O)(O)=O)C=C1
  • InChIKey: VWFCHDSQECPREK-LURJTMIESA-N
  • Mol. Mass: 279.187
  • ALogP: -1.66
  • ChEMBL Molecules:
    cidofovir  
    cidofovir  
More Chemistry

Pharmacology

Alternative names

1-((3-hydroxy-2-phosphonylmethoxy)propyl)cytosine | 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine | 1-(s)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine | 1-[(s)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine | anhydrous cidofovir | cdv | cidofovir | cidofovir anhydrous | cidofovir dihydrate | cidofovir hydrate | cidofovir, (+-)-isomer | cidofovir monophosphate | cidofovir, (r)-isomer | cidofovir sodium | cidofovir, sodium salt | cidofovirum | cidovir | gs-0504 | gs 504 | gs-504 | hpmpc | (s)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine | (s)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine | (s)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine | ({[(s)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid | [[(s)-2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid | [(s)-2-(4-amino-2-oxo-2h-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid | (s)-(3-(4-amino-2-oxopyrimidin-1(2h)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid | (s)-hpmpc | sidofovir | vistide

Organizations (41)

Research & Development (38)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (2)


 

Cytomegalovirus Retinitis (approved 1996)

Primary Immunodeficiency Diseases

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Acute Kidney Injury (Phase 4)

Anus Neoplasms (Phase 2)

Bone Marrow Cells (Phase 1)

Condylomata Acuminata (Phase 1)

Cytomegalovirus Infections (Phase 3)

Cytomegalovirus Retinitis (Phase 4)

Hair (Phase 2)

Herpes Simplex (Phase 1)

HIV Infections (Phase 4)

Kidney Diseases (Phase 1/Phase 2)

Lung Diseases (Phase 4)

Neoplasms (Phase 3)

Papilloma (Phase 1)

Precancerous Conditions (Phase 2)

Sarcoma (Phase 2)

Transplantation (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial Organizations: 38

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue